Genes with epigenetic alterations in human pancreatic islets impact mitochondrial function, insulin secretion, and type 2 diabetes

Tina Rönn,Jones K. Ofori,Alexander Perfilyev,Alexander Hamilton,Karolina Pircs,Fabian Eichelmann,Sonia Garcia-Calzon,Alexandros Karagiannopoulos,Hans Stenlund,Anna Wendt,Petr Volkov,Matthias B. Schulze,Hindrik Mulder,Lena Eliasson,Sabrina Ruhrmann,Karl Bacos,Charlotte Ling
DOI: https://doi.org/10.1038/s41467-023-43719-9
IF: 16.6
2023-12-12
Nature Communications
Abstract:Abstract Epigenetic dysregulation may influence disease progression. Here we explore whether epigenetic alterations in human pancreatic islets impact insulin secretion and type 2 diabetes (T2D). In islets, 5,584 DNA methylation sites exhibit alterations in T2D cases versus controls and are associated with HbA1c in individuals not diagnosed with T2D. T2D-associated methylation changes are found in enhancers and regions bound by β-cell-specific transcription factors and associated with reduced expression of e.g. CABLES1 , FOXP1 , GABRA2 , GLR1A , RHOT1 , and TBC1D4 . We find RHOT1 (MIRO1) to be a key regulator of insulin secretion in human islets. Rhot1 -deficiency in β-cells leads to reduced insulin secretion, ATP/ADP ratio, mitochondrial mass, Ca 2+ , and respiration. Regulators of mitochondrial dynamics and metabolites, including L-proline, glycine, GABA, and carnitines, are altered in Rhot1 -deficient β-cells. Islets from diabetic GK rats present Rhot1-deficiency. Finally, RHOT1 methylation in blood is associated with future T2D. Together, individuals with T2D exhibit epigenetic alterations linked to mitochondrial dysfunction in pancreatic islets.
multidisciplinary sciences
What problem does this paper attempt to address?